Performance of Medometer visual tool for measuring medication adherence and comparison with other measures.

Hansen RA, Esserman DA, Roth MT, Lewis C, Burkhart JI, Weinberger M, Watson LC. Performance of Medometer visual tool for measuring medication adherence and comparison with other measures. Journal of the American Pharmacists Association : JAPhA. 2013 Mar 1; 53(2):198-205.

Related HSR&D Project(s)

• RCS 91-408 – Research Career Scientist Award

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

OBJECTIVES: To measure adherence in older adults with the use of a novel visual scale screening tool and to compare this adherence measurement with other adherence measures. DESIGN: Noncontrolled prospective intervention trial. SETTING: Geriatric psychiatry clinic in North Carolina between February 2008 and July 2009. PARTICIPANTS: 27 geriatric psychiatry clinic patients were identified as meeting eligibility criteria, and 26 of these participants completed the baseline and 3- and 6-month visits. INTERVENTION: Pharmacist-provided medication management program. MAIN OUTCOME MEASURES: A novel visual scale, the Medometer, assessed patient adherence to individual medications and aggregate medication regimen. The Medometer was compared with pharmacist subjective adherence assessment and the four-item Morisky scale. RESULTS: Aggregate regimen adherence based on the Morisky scale was 44%, 50%, and 38% at baseline, 3 months, and 6 months, respectively. Similarly it was 48%, 50%, and 46%, respectively, for the aggregate Medometer measurement. Measured individually by drug, average adherence at baseline, 3 months, and 6 months was 44%, 50%, and 35%, respectively, with the Medometer and 74%, 65%, and 50%, respectively, for the pharmacist's subjective assessment. Less stringent definitions for categorizing adherence identified a higher proportion of patients as adherent, with similar trends across measures. Individual medication and aggregate regimen adherence estimates provided face validity for the Medometer, with moderate agreement with other measures. CONCLUSION: The Medometer is a visual scale that can assess individual medication and overall medication regimen adherence. It performed well in this pilot study, but additional research is needed to assess the reliability and validity of this tool in larger, diverse populations and to test the effectiveness of this tool in guiding pharmacists' efforts to improve medication outcomes.